According to the latest market research study released by Technavio, the global prostate cancer drugs market is expected to grow at a CAGR of around 9% during the forecast period 2016-2020.
This market research report by Technavio provides an in-depth analysis of the market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Click here to request a free sample of this report
Technavio research analysts categorize the global prostate cancer drugs market based on therapy:
Global prostate cancer drugs market shares by therapy 2015
|
Hormonal therapy |
80% |
|
Chemotherapy |
10% |
|
Immunotherapy |
6% |
|
Targeted therapy |
4% |
Source: Technavio
Hormonal therapy
Hormonal therapy occupied the maximum share of around 80% in the global prostate cancer drugs market. This therapy involves the application of several pharmacologic agents that help in the reduction of testosterone levels in men. Hormonal therapy is segmented into LHRH (luteinizing hormone-releasing hormone) antagonists (Firmagon), LHRH analogs (Zoladex, Lupron, Eligard, Vantas, and Decapeptyl), and antiandrogens (Casodex).
“The high growth of this segment can be attributed to the presence of a significant number of drugs in the market. Some of the drugs that have established their presence in the market include Lupron and Zoladex. A few novel hormonal therapies such as Zytiga and Xtandi will continue to dominate the market, which indicates that the innovative therapies are widely accepted among physicians owing to their effectiveness in treatment,” says Sapna Jha, a lead analyst at Technavio for research on in-vitro diagnostics.
Chemotherapy
Chemotherapy is not a normal treatment for early prostate cancer, but is used in cases where hormonal therapy does not work. Chemotherapy drugs is useful for cancers that have metastasized to distant organs. Some of the chemo drugs used for the treatment of prostate cancer includes Taxotere, Jevtana, Taxol, Novantrone, and Velban. The emergence of combination drugs is another factor which is expected to have a positive influence on the growth of this segment. Chemotherapy drugs are given when the hormonal therapy alone does not work to treat prostate cancer, and helps improve the overall survival rates. For instance, recently, Sanofi announced that Jevtana has received NICE (National Institute for Health and Care Excellence) recommendation for use in combination with prednisone as a treatment for metastatic-relapsed prostate cancer.
Immunotherapy
Immunotherapy is the treatment for advanced or recurrent forms of prostate cancer and makes use of the body’s immune system to fight cancer. Immunotherapy works by either stimulating the immune system to attack cancer cells or by providing the immune system with antibodies to strive with cancer. This treatment method may be used alone or in combination with other treatments, such as radiation therapy and hormone therapy. There are some common types of immunotherapy which include monoclonal antibodies, cancer vaccines, and non-specific immunotherapies. Many potential immunotherapies are in several development phases and, once launched, will boost the market growth during the forecast period. Some of the immunotherapy candidates for the treatment of prostate cancer include ProstVac and Yervoy, DCVax-Prostate, DCVAC/PCa, and ProstAtak.
Targeted therapy
Targeted therapy is used for treating prostate cancer when it reoccurs or when a patient’s tumor can be made under control at an earlier stage by manipulating its growth signals. This therapy makes use of drugs that help identify and attack the cancer cells, while little damage is done to the normal cells. For instance, Cabozantinib is a new drug that targets the methionine (MET) protein and influences the vascular endothelial growth factor. Moreover, Xofigo has reported a revenue of around USD 285 million in 2015, which shows the increased interest of physicians in targeted therapies.
The top leading vendors operating in the global prostate cancer drugs market are:
- AbbVie
- Astellas Pharma
- AstraZeneca
- Johnson & Johnson
- Sanofi
Other prominent vendors in the market include Active Biotech, ADC Therapeutics, Advantagene, Advaxis Pharmaceuticals, ANI Pharmaceuticals, ArQule, Athenex Pharmaceuticals, Bavarian Nordic, Bayer HealthCare, BHR Pharma, BMS, Boehringer Ingelheim, Camurus, Cleveland BioLabs, CureVac, Dendreon, Dextech Medical, Eisai, Endo Pharmaceuticals, Ferring Pharmaceutical, Foresee Pharmaceuticals, GlaxoSmithKline, GTx, Innocrin Pharmaceutical, Inspyr Therapeutics, Io Therapeutics, Lidds AB, Merck Group, Myovant Sciences, Northwest Biotherapeutics, Novartis, Nymox Pharmaceuticals, OncoGenex, Oncolytics Biotech, Orion, Pharmamar, Progenics Pharmaceuticals, Sotio, Spectrum Pharmaceuticals, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, and Tokai Pharmaceuticals.
A more detailed analysis is available in the Technavio report titled, ‘Global Prostate Cancer Drugs Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Cancer Diagnostic Devices Market 2016-2020
- Global Alopecia Drugs Market 2016-2020
- Global Erectile Dysfunction Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
